473 related articles for article (PubMed ID: 17976724)
1. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
2. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
Fletcher EC; Lade RJ; Adewoyin T; Chong NV
Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
[TBL] [Abstract][Full Text] [Related]
3. Value-based medicine.
Kymes SM; Vollman D; Frick KD
Ophthalmology; 2008 Nov; 115(11):2099; author reply 2100. PubMed ID: 19068385
[No Abstract] [Full Text] [Related]
4. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A
Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
[TBL] [Abstract][Full Text] [Related]
5. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
[TBL] [Abstract][Full Text] [Related]
7. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Boyer DS; Antoszyk AN; Awh CC; Bhisitkul RB; Shapiro H; Acharya NR;
Ophthalmology; 2007 Feb; 114(2):246-52. PubMed ID: 17270674
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic approaches to age-related macular degeneration today.
Bressler NM
Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: Model analysis from the perspective of Germany's statutory health insurance system.
Neubauer AS; Holz FG; Sauer S; Wasmuth T; Hirneiss C; Kampik A; Schrader W
Clin Ther; 2010 Jul; 32(7):1343-56. PubMed ID: 20678682
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Heier JS; Antoszyk AN; Pavan PR; Leff SR; Rosenfeld PJ; Ciulla TA; Dreyer RF; Gentile RC; Sy JP; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):633.e1-4. PubMed ID: 16483659
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
[TBL] [Abstract][Full Text] [Related]
12. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
[TBL] [Abstract][Full Text] [Related]
14. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
15. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
Brown GC; Brown MM; Brown HC; Kindermann S; Sharma S
Ophthalmology; 2007 Jun; 114(6):1170-8. PubMed ID: 17320964
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
[TBL] [Abstract][Full Text] [Related]
17. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data.
Brown GC; Brown MM; Campanella J; Beauchamp GR
Am J Ophthalmol; 2005 Oct; 140(4):679-87. PubMed ID: 16226519
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
20. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
